Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 6
1990 18
1991 30
1992 45
1993 48
1994 66
1995 57
1996 96
1997 67
1998 59
1999 63
2000 58
2001 49
2002 48
2003 49
2004 39
2005 46
2006 38
2007 48
2008 44
2009 48
2010 56
2011 49
2012 30
2013 41
2014 49
2015 47
2016 34
2017 35
2018 31
2019 35
2020 37
2021 26
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,380 results
Results by year
Filters applied: . Clear all
Page 1
Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Ruberto AJ, et al. Ann Emerg Med. 2021 Jun;77(6):613-619. doi: 10.1016/j.annemergmed.2020.08.021. Epub 2020 Nov 5. Ann Emerg Med. 2021. PMID: 33160719 Clinical Trial.
CONCLUSION: In this clinical trial, haloperidol was superior to ondansetron for the acute treatment of cannabis-associated hyperemesis. The efficacy of haloperidol over ondansetron provides insight into the pathophysiology of this now common diagnosis in many EDs... …
CONCLUSION: In this clinical trial, haloperidol was superior to ondansetron for the acute treatment of cannabis-associated hyperemesi …
Bimodal Release Ondansetron for Acute Gastroenteritis Among Adolescents and Adults: A Randomized Clinical Trial.
Silverman RA, House SL, Meltzer AC, Hahn B, Lovato LM, Avarello J, Miller JB, Kalfus IN, Fathi R, Raday G, Plasse TF, Yan EC. Silverman RA, et al. JAMA Netw Open. 2019 Nov 1;2(11):e1914988. doi: 10.1001/jamanetworkopen.2019.14988. JAMA Netw Open. 2019. PMID: 31702802 Free PMC article. Clinical Trial.
Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. INTERVENTION: Bimodal release ondansetron tablet containing 6 mg of immediate release ondansetron and 18 mg of a 24-hour release matrix for a total of 24 mg of …
Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. INTERVENTION: Bimodal release o
Aromatherapy Versus Oral Ondansetron for Antiemetic Therapy Among Adult Emergency Department Patients: A Randomized Controlled Trial.
April MD, Oliver JJ, Davis WT, Ong D, Simon EM, Ng PC, Hunter CJ. April MD, et al. Ann Emerg Med. 2018 Aug;72(2):184-193. doi: 10.1016/j.annemergmed.2018.01.016. Epub 2018 Feb 17. Ann Emerg Med. 2018. PMID: 29463461 Clinical Trial.
We randomized subjects to 1 of 3 arms: inhaled isopropyl alcohol and 4 mg oral ondansetron, inhaled isopropyl alcohol and oral placebo, and inhaled saline solution placebo and 4 mg oral ondansetron. ...CONCLUSION: Among ED patients with acute nausea and not requirin …
We randomized subjects to 1 of 3 arms: inhaled isopropyl alcohol and 4 mg oral ondansetron, inhaled isopropyl alcohol and oral placeb …
Comparison of nalbuphine, ondansetron and placebo for the prevention of shivering after spinal anaesthesia for urgent caesarean delivery: a randomised double-blind controlled clinical trial.
Liu J, Huang S, Sun S, Sun X, Wang T. Liu J, et al. Int J Obstet Anesth. 2020 May;42:39-46. doi: 10.1016/j.ijoa.2019.10.002. Epub 2019 Oct 24. Int J Obstet Anesth. 2020. PMID: 31734098 Clinical Trial.
We tested the hypothesis that prophylactic nalbuphine and ondansetron can prevent post-spinal anaesthesia shivering in parturients undergoing urgent caesarean delivery. ...CONCLUSION: Nalbuphine 0.08 mg/kg can prevent post-spinal anaesthesia shivering in parturients underg …
We tested the hypothesis that prophylactic nalbuphine and ondansetron can prevent post-spinal anaesthesia shivering in parturients un …
Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting Following General Anesthesia: A Randomized Clinical Trial.
Yazbeck-Karam VG, Siddik-Sayyid SM, Barakat HB, Korjian S, Aouad MT. Yazbeck-Karam VG, et al. Anesth Analg. 2017 Feb;124(2):438-444. doi: 10.1213/ANE.0000000000001723. Anesth Analg. 2017. PMID: 28002167 Clinical Trial.
One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = 60). RESULTS: Data from 112 patients (59 in the haloperidol group and 53 in the ondansetron group) were analyzed. ...Thus, it is noni …
One hundred twenty patients with PONV received either haloperidol 1 mg intravenously (n = 60) or ondansetron 4 mg intravenously (n = …
A randomized, double-blind, placebo-controlled proof-of-concept study of ondansetron for bipolar and related disorders and alcohol use disorder.
Sherwood Brown E, McArdle M, Palka J, Bice C, Ivleva E, Nakamura A, McNutt M, Patel Z, Holmes T, Tipton S. Sherwood Brown E, et al. Eur Neuropsychopharmacol. 2021 Feb;43:92-101. doi: 10.1016/j.euroneuro.2020.12.006. Epub 2021 Jan 2. Eur Neuropsychopharmacol. 2021. PMID: 33402258 Clinical Trial.
Inclusion of SNPs increased effect sizes for some alcohol-related outcomes and the HRSD. Ondansetron was well tolerated. This proof-of-concept study is the first report on ondansetron in bipolar people with bipolar disorders and alcohol use disorder. ...A larger tri …
Inclusion of SNPs increased effect sizes for some alcohol-related outcomes and the HRSD. Ondansetron was well tolerated. This proof-o …
Clinical pharmacology of ondansetron in postoperative nausea and vomiting.
Baber N, Palmer JL, Frazer NM, Pritchard JF. Baber N, et al. Eur J Anaesthesiol Suppl. 1992 Nov;6:11-8. Eur J Anaesthesiol Suppl. 1992. PMID: 1425620 Review.
Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%. ...There is no evidence for effects of ondansetron on cardiac function (electrocardiogram, cardiac output, blood pressure and heart rate), and haem
Ondansetron is rapidly absorbed after oral administration (tmax 1.9 h) with an absolute bioavailability of around 60%. ...There is no
High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions.
Stern ER, Shahab R, Grimaldi SJ, Leibu E, Murrough JW, Fleysher L, Parides MK, Coffey BJ, Burdick KE, Goodman WK. Stern ER, et al. Neuropsychopharmacology. 2019 Jan;44(2):390-398. doi: 10.1038/s41386-018-0174-x. Epub 2018 Aug 8. Neuropsychopharmacology. 2019. PMID: 30116006 Free PMC article. Clinical Trial.
These effects were driven by a robust reduction in activation for ondansetron compared to placebo for the 24-mg group, with weaker effects for the 16-mg and 8-mg groups. In conclusion, high-dose ondansetron reduces activation of several areas important for interocep …
These effects were driven by a robust reduction in activation for ondansetron compared to placebo for the 24-mg group, with weaker ef …
Ondansetron does not reduce the shivering threshold in healthy volunteers.
Komatsu R, Orhan-Sungur M, In J, Podranski T, Bouillon T, Lauber R, Rohrbach S, Sessler D. Komatsu R, et al. Br J Anaesth. 2006 Jun;96(6):732-7. doi: 10.1093/bja/ael101. Epub 2006 May 4. Br J Anaesth. 2006. PMID: 16675509 Free PMC article. Review.
BACKGROUND: Ondansetron, a serotonin-3 receptor antagonist, reduces postoperative shivering. ...Ondansetron did not change the sweating (control 37.4 (0.4) degrees C, ondansetron 37.6 (0.3) degrees C, P=0.16), vasoconstriction (37.0 (0.5) degrees C vs 37.1 (0 …
BACKGROUND: Ondansetron, a serotonin-3 receptor antagonist, reduces postoperative shivering. ...Ondansetron did not change the …
1,380 results